Completed PHASE1/PHASE2 INTERVENTIONAL NCT00066885

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

A Phase 1/2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Previous Therapy With Platinum-Based Chemotherapy

Sponsor: Aventis Pharmaceuticals

Conditions Carcinoma, Non-Small-Cell Lung

Interventions calcitriol + docetaxel

Updated 5 times since 2017 Last updated: May 3, 2007 Started: Jun 30, 2003 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Carcinoma, Non-Small-Cell Lung and is currently completed. Aventis Pharmaceuticals leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aventis Pharmaceuticals
Novacea

Data source: Novacea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Berkeley, United States , Denver, United States , Greenville, United States , Portland, United States , Seattle, United States , Tulsa, United States , Vallejo, United States , Vancouver, United States , Winston-Salem, United States and 1 more location